These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
720 related articles for article (PubMed ID: 17558264)
41. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794 [TBL] [Abstract][Full Text] [Related]
42. The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder. Harpe SE; Szeinbach SL; Caswell RJ; Corey R; McAuley JW J Urol; 2007 Dec; 178(6):2532-6; discussion 2536. PubMed ID: 17937937 [TBL] [Abstract][Full Text] [Related]
43. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Wennberg AL; Molander U; Fall M; Edlund C; Peeker R; Milsom I Eur Urol; 2009 Apr; 55(4):783-91. PubMed ID: 19157689 [TBL] [Abstract][Full Text] [Related]
44. Defining the role of overactive bladder treatments in men with lower urinary tract symptoms. Lemack GE Nat Clin Pract Urol; 2007 Apr; 4(4):174-5. PubMed ID: 17415351 [No Abstract] [Full Text] [Related]
46. Understanding the elements of overactive bladder: questions raised by the EPIC study. Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K; BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602 [TBL] [Abstract][Full Text] [Related]
47. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659 [TBL] [Abstract][Full Text] [Related]
48. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474 [TBL] [Abstract][Full Text] [Related]
49. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M; BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143 [TBL] [Abstract][Full Text] [Related]
50. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy. Roumeguère T Eur Urol; 2008 Oct; 54(4):916-7. PubMed ID: 18036722 [No Abstract] [Full Text] [Related]
51. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy. Kuo HC Eur Urol; 2008 Oct; 54(4):915-6. PubMed ID: 18036725 [No Abstract] [Full Text] [Related]
52. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. Wein AJ; Rackley RR J Urol; 2006 Mar; 175(3 Pt 2):S5-10. PubMed ID: 16458739 [TBL] [Abstract][Full Text] [Related]
54. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890 [TBL] [Abstract][Full Text] [Related]